Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study
Modern Rheumatology · 2023
DOI: 10.1093/mr/roac133 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Katsuhiko Takabayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Informatics and Management, Chiba University Hospital, Chiba, Japan. Hauptthemen laut MEDLINE: Pneumonia, Pneumocystis, Arthritis, Rheumatoid, Opportunistic Infections, Tuberculosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Grants-in-Aid for Scientific Research-KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology.
Abstract (Originalsprache)
Objectives
We compared the incidences of four opportunistic infections (OIs) in patients with rheumatoid arthritis (RA) treated with molecular-targeted drugs from big claims data. Materials and Methods We identified 205,906 patients with RA who were prescribed molecular-targeted drugs in 2010–17 from the National Database of Japan and calculated the incidence of four OIs (Pneumocystis pneumonia, tuberculosis, nontuberculous mycobacterial infection, and herpes zoster).
Results
The total number of Pneumocystis pneumonia, tuberculosis, nontuberculous mycobacterial infection, and herpes zoster patients with biological disease-modifying antirheumatic drugs or tofacitinib treatment history in RA was 765, 1158, 834, and 18,336, respectively. The incidence rates of each OI for all biological disease-modifying antirheumatic drugs were 0.14, 0.14, 0.09, and 2.40 per 100 person-years, respectively, while for tofacitinib they were 0.22, 0.22, 0.07, and 7.00 per 100 person-years. No big difference was observed among biological disease-modifying antirheumatic drugs. All OIs showed higher incidence in those >65 years, but Pneumocystis pneumonia, nontuberculous mycobacterial infection, and herpes zoster showed no difference between those 65–74 years old and those >75 years old. The median of occurrence was the third, seventh, ninth, and thirteenth month after treatment, respectively.
Conclusions
We counted real incidence rates of OIs for the whole nation from big claims data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Informatics and Management, Chiba University Hospital, Chiba, Japan.
- Department of Internal Medicine, Sanwa Hospital, Chiba, Japan.
- Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan.
- Clinical Research Center, Chiba University Hospital, Chiba, Japan.
ORCID-Profile: Katsuhiko Takabayashi, Kei Ikeda
Förderung
- Grants-in-Aid for Scientific Research-KAKENHI from the Ministry of Education, Culture, Sports, Science and Technology
Zitieren
APA
Takabayashi, K., Ando, F., Ikeda, K., Nakajima, H., Hanaoka, H., & Suzuki, T. (2023). Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study. Modern Rheumatology. https://doi.org/10.1093/mr/roac133
Vancouver
Takabayashi K, Ando F, Ikeda K, Nakajima H, Hanaoka H, Suzuki T. Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study. Modern Rheumatology. 2023. doi:10.1093/mr/roac133
BibTeX
@article{Takabayashi2023,
author = {Takabayashi, Katsuhiko and Ando, Fumihiko and Ikeda, Kei and Nakajima, Hiroshi and Hanaoka, Hideki and Suzuki, Takahiro},
title = {Incidence of opportunistic infections in patients with rheumatoid arthritis treated with different molecular-targeted drugs: A population-based retrospective cohort study},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roac133}
}
EUVIMED